Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients

Arvindakshan, Meena, Sitasawad, Sandhya, Debsikdar, Vijay, Ghate, Madhav, Evans, Denise, Horrobin, David F, Bennett, Crispin, Ranjekar, Prabhakar K, Mahadik, Sahebarao P · 2003 · Biological Psychiatry

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(02)01443-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 56

  1. Arvindakshan M (2002): The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune, India: Pune University Press
  2. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP (in press): Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res · DOI · Paper page
  3. Assies, 2001, Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group, Biol Psychiatry, 49, 510, 10.1016/S0006-3223(00)00986-0 · DOI · Paper page
  4. Axelrod, 1990, Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction, Biochem Soc Trans, 18, 503, 10.1042/bst0180503 · doi:10.1042/bst0180503
  5. Bloom, 1993, Advancing a neurodevelopmental origin for schizophrenia, Arch Gen Psychiatry, 50, 224, 10.1001/archpsyc.1993.01820150074008 · DOI · Paper page
  6. Cadet, 1987, Free radicals and the developmental pathophysiology of schizophrenia burnout, Integr Psychiatry, 5, 40
  7. Carlson, 1986, High fat diets varying ratios of polyunsaturated to saturated fatty acids and linolenic acid, a comparison of rat neural and red cell membrane phospholipids, J Nutr, 116, 718, 10.1093/jn/116.5.718 · DOI · Paper page
  8. Carpenter, 1988, Deficit and non-deficit forms of schizophrenia, Am J Psychiatry, 145, 578, 10.1176/ajp.145.5.578 · DOI · Paper page
  9. Evans, 2001, Cell membrane essential fatty acid status in drug-naïve first-episode psychotic patients and its relation to outcome, Schizophr Res, 49, 83
  10. Fenton, 2001, A placebo-controlled trial of omega-3 fatty acids (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, Am J Psychiatry, 158, 2071, 10.1176/appi.ajp.158.12.2071 · DOI · Paper page
  11. Fenton, 2000, Essential fatty acids, lipid membrane abnormalities, and the diagnosis of schizophrenia, Biol Psychiatry, 47, 8, 10.1016/S0006-3223(99)00092-X · DOI · Paper page
  12. Fujimoto, 1992, Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging, Acta Psychiatr Scand, 86, 455, 10.1111/j.1600-0447.1992.tb03297.x · DOI
  13. Fukuzako, 1996, Phosphorus magnetic resonance spectroscopy in schizophrenia, Progr Neuropsychopharmacol Biol Psychiatry, 20, 629, 10.1016/0278-5846(96)00036-X · DOI
  14. Gattaz, 1990, Increased serum phospholipase A2 activity in schizophrenia, Biol Psychiatry, 28, 495
  15. Glen, 1994, A red cell membrane abnormality in a subgroup of schizophrenic patients, Schizophr Res, 12, 53, 10.1016/0920-9964(94)90084-1 · DOI · Paper page
  16. Horrobin, 1996, Schizophrenia as a membrane lipid disorder, which is expressed throughout the body, Prostaglandin Leukotr Essent Fatty Acids, 55, 3, 10.1016/S0952-3278(96)90138-6 · DOI
  17. Horrobin, 1998, The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia, Schizophr Res, 30, 193, 10.1016/S0920-9964(97)00151-5 · DOI · Paper page
  18. Horrobin, 1994, The membrane hypothesis of schizophrenia, Schizophr Res, 13, 195, 10.1016/0920-9964(94)90043-4 · DOI · Paper page
  19. Horrobin, 1991, Fatty acid levels in the brains of schizophrenics and normal control subjects, Biol Psychiatry, 30, 795, 10.1016/0006-3223(91)90235-E · DOI · Paper page
  20. Hudson, 1996, Genetic variant near cytosolic phospholipase A2 associated with schizophrenia, Schizophr Res, 21, 111, 10.1016/0920-9964(96)00031-X · DOI
  21. Hudson, 1993, CNS signal transduction and pathophysiology and pharmacotherapy of affective disorder and schizophrenia, Synapse, 13, 278, 10.1002/syn.890130311 · DOI
  22. Jedding, 1995, Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs, Biochem Pharmacol, 49, 359, 10.1016/0006-2952(94)00424-K · DOI
  23. Joffe, 1998, Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?, Schizophr Res, 29, 172, 10.1016/S0920-9964(97)88746-4 · doi:10.1016/s0920-9964(97)88746-4
  24. Katila, 1997, No differences in phospholipase-A2 activity between acute psychiatric patients and control subjects, Schizophr Res, 26, 103, 10.1016/S0920-9964(97)00054-6 · doi:10.1016/s0920-9964(97)00054-6
  25. Keshavan, 1993, Erythrocyte membrane phospholipids in psychotic patients, Psychiatry Res, 49, 89, 10.1016/0165-1781(93)90032-C · DOI
  26. Keshavan, 1993, Frontal lobe metabolism & cerebral morphology in schizophrenics, Schizophr Res, 10, 241, 10.1016/0920-9964(93)90058-Q · DOI
  27. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (in press): Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res · DOI · Paper page
  28. Konings, 1979, Radiation effects on membranes I, Radiation Res, 80, 494, 10.2307/3574991 · DOI
  29. Kramer, 1987, The effects of ischemia and recirculation, hypoxia and recovery on antioxidant factors and α-adrenoreceptor density, Biochem Biophys Res Commun, 149, 568, 10.1016/0006-291X(87)90405-0 · DOI
  30. Mahadik, 2001, Oxidative stress and role of antioxidant and −3 essential fatty acid supplementation in schizophrenia, Progr Neuropsychopharmacol Biol Psychiatry, 25, 263, 10.1016/S0278-5846(00)00181-0 · DOI · Paper page
  31. Mahadik, 1996, Free radical pathology and antioxidant defense in schizophrenia, Schizophr Res, 19, 1, 10.1016/0920-9964(95)00049-6 · DOI · Paper page
  32. Mahadik, 1994, Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naïve patients at the onset of psychosis, Schizophr Res, 13, 239, 10.1016/0920-9964(94)90048-5 · DOI
  33. Mahadik, 1996, Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients, Psychiatry Res, 63, 133, 10.1016/0165-1781(96)02899-5 · DOI
  34. Mahadik, 1998, Elevated plasma lipid peroxides at the onset of nonaffective psychosis, Biol Psychiatry, 43, 674, 10.1016/S0006-3223(97)00282-5 · DOI · Paper page
  35. Manku MS, Horrobin DF, Huang S, Morse N (1983): Fatty acids in plasma and red cell membranes. Lipids 18:906–908. · DOI · Paper page
  36. McCreadie, 1995, The Nithsdale Schizophrenia Surveys. XIV. Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects, Br J Psychiatry, 167, 610, 10.1192/bjp.167.5.610 · DOI
  37. Nasrallah, 1993, Neurodevelopmental pathogenesis of schizophrenia, Psychiatr Clin North Am, 16, 269, 10.1016/S0193-953X(18)30173-4 · DOI
  38. Neuringer, 1986, Biochemical and functional effects of prenatal and post-natal ω-3 fatty acid deficiency on retina and brain in rhesus monkeys, Proc Natl Acad Sci U S A, 83, 4021, 10.1073/pnas.83.11.4021 · DOI · Paper page
  39. Peet, 2002, A dose ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, J Psychiatric Res, 36, 7, 10.1016/S0022-3956(01)00048-6 · DOI · Paper page
  40. Peet, 1995, Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients, J Psychiatr Res, 29, 227, 10.1016/0022-3956(95)00001-L · DOI
  41. Peet, 1996, Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients and the clinical effects of dietary supplementation, Prostagland Leukotr Essent Fatty Acids, 55, 71, 10.1016/S0952-3278(96)90148-9 · DOI · Paper page
  42. Pettegrew, 1991, Alterations in brain high energy phosphate and membrane phospholipid metabolism in first-episode, drug-naïve schizophrenics. A pilot study of dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy, Arch Gen Psychiatry, 48, 563, 10.1001/archpsyc.1991.01810300075011 · DOI · Paper page
  43. Reddy, 1996, Free radical pathology in schizophrenia, Prostagland Leukotr Essent Fatty Acids, 55, 33, 10.1016/S0952-3278(96)90143-X · DOI · Paper page
  44. Reddy, 1999, Essential fatty acids and outcome in first-episode schizophrenia, Schizophr Res, 36, 108
  45. Richardson, 2001, Association between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes, Progr Neuropsychopharmacol Biol Psychiatry, 25, 1513, 10.1016/S0278-5846(01)00211-1 · DOI
  46. Stanley, 1994, Membrane phospholipid metabolism and schizophrenia, Schizophr Res, 13, 209, 10.1016/0920-9964(94)90044-2 · DOI
  47. Vaddadi, 1996, Dyskinesias and their treatment with EFAs, Prostagland Leukotr Essent Fatty Acids, 55, 89, 10.1016/S0952-3278(96)90151-9 · DOI
  48. Vaddadi, 1989, A double-blind trial of essential fatty acids supplementation in patients with tardive dyskinesia, Psychiatry Res, 27, 313, 10.1016/0165-1781(89)90146-7 · DOI
  49. Wainwright, 1992, Do essential fatty acids play a role in brain and behavioral development?, Neurosci Biobehavioral Rev, 16, 193, 10.1016/S0149-7634(05)80180-0 · DOI · Paper page
  50. Weinberger, 1987, Implications of normal brain development for the pathogenesis of schizophrenia, Arch Gen Psychiatry, 44, 660, 10.1001/archpsyc.1987.01800190080012 · DOI · Paper page
  51. 1973, Vol. 1
  52. Wyatt, 1997, Long-term morbidity associated with delayed treatment of admission schizophrenic patients, Psychol Med, 27, 261, 10.1017/S0033291796004345 · DOI
  53. Wyatt, 2001, Rationale for the study of early intervention, Schizophr Res, 51, 69, 10.1016/S0920-9964(01)00242-0 · DOI
  54. Yao, 2000, Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients, Schizophr Res, 42, 7, 10.1016/S0920-9964(99)00095-X · DOI · Paper page
  55. Yao, 1994, Red blood cell membrane dynamics II, Schizophr Res, 13, 217, 10.1016/0920-9964(94)90045-0 · DOI
  56. Yao, 1992, Increased turnover of platelet phosphatidylinositol in schizophrenia, Prostagland Leukotr Essent Fatty Acids, 46, 39, 10.1016/0952-3278(92)90057-P · DOI

Cited by

See all 232

Metadata

Authors
Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., Bennett, C., Ranjekar, P. K., & Mahadik, S. P.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2003-01
Volume
53
Issue
1
Pages
56-64
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2020818277
Cited by
232
References
6
FWCI
10.74
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. https://app.cochat.ai/papers/10.1016/s0006-3223(02)01443-9
The paper
Arvindakshan, M., Sitasawad, S., Debsikdar, V., Ghate, M., Evans, D., Horrobin, D. F., Bennett, C., Ranjekar, P. K., & Mahadik, S. P. (2003). Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(02)01443-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.